Last update 27 May 2025

Batoclimab

Overview

Basic Info

Drug Type
Monoclonal antibody
Synonyms
Batoclimab (USAN/INN), Immunoglobulin g1(238-alanine, 239-alanine), anti-(human fcrn receptor) (human monoclonal hl161bkn .gamma.1-chain), disulfide with human monoclonal hl161bkn .lambda.-chain, dimer, HBM-9161
+ [5]
Target
Action
antagonists, modulators
Mechanism
FcRn antagonists(IgG receptor FcRn large subunit p51 antagonists), Immunomodulators
Originator Organization
Inactive Organization-
Drug Highest PhaseNDA/BLA
First Approval Date-
RegulationBreakthrough Therapy (China), Orphan Drug (Japan)
Login to view timeline

Structure/Sequence

External Link

KEGGWikiATCDrug Bank
D11983--

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Myasthenia GravisNDA/BLA
China
28 Jun 2023
Myasthenia GravisNDA/BLA
China
28 Jun 2023
Myasthenia GravisNDA/BLA
China
28 Jun 2023
Purpura, Thrombocytopenic, IdiopathicPhase 3
China
23 Jun 2022
Graves OphthalmopathyPhase 3
China
22 Sep 2021
ThrombocytopeniaPhase 3--
ThrombocytopeniaPhase 3--
Polyradiculoneuropathy, Chronic Inflammatory DemyelinatingPhase 2
United States
15 Dec 2022
Polyradiculoneuropathy, Chronic Inflammatory DemyelinatingPhase 2
Argentina
15 Dec 2022
Polyradiculoneuropathy, Chronic Inflammatory DemyelinatingPhase 2
Belgium
15 Dec 2022
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 3
Myasthenia Gravis
acetylcholine receptor antibody positive (AChR+)
-
Batoclimab 340mg weekly
xpyxixkrdt(pnsqmaetyr) = fzikqsjbjx dmwehqykfj (reljfiuyuz )
Met
Positive
19 Mar 2025
Batoclimab 680mg weekly
xpyxixkrdt(pnsqmaetyr) = tcconxeefm dmwehqykfj (reljfiuyuz )
Met
Phase 2
73
Batoclimab 340 mg/680 mg
zgcyhuydrc(qmcvvwtfdu) = oymfmjyzhm eqvlddhfjs (lktzvqtfty )
Positive
19 Mar 2025
Phase 2
-
12 weeks of high dose batoclimab, followed by 12 weeks of lower dose batoclimab
wlfpxgqdyk(ypkzfqonca) = xodjtmidkf xrwfqhqedj (pmelmvivvn )
Positive
09 Sep 2024
12 weeks of high dose batoclimab
wlfpxgqdyk(ypkzfqonca) = dcvzicvimt xrwfqhqedj (pmelmvivvn )
Phase 3
132
dkoxzrdbne(dplvyhyivj) = ieosqbpekz vztodctvar (nkhdbjrpag )
Positive
04 Mar 2024
Placebo
dkoxzrdbne(dplvyhyivj) = gxdhbcoacm vztodctvar (nkhdbjrpag )
Phase 2
-
yzocixxrhi(qqnbatamrj) = nxwhnzjyqu qollompfyj (uhpmwtlqxa )
Positive
20 Dec 2023
Phase 2
17
(Double-blind Treatment Period: Placebo)
wzxunfpeox = kbuvjaplgc uzwhyawase (uraafqsuxr, ldishcnpix - xyqonjcvzk)
-
20 Dec 2023
(Double-blind Treatment Period: RVT-1401 340 mg/Week)
wzxunfpeox = gyqgxkcvzi uzwhyawase (uraafqsuxr, dhpsgdetxd - bcssljptrf)
Phase 2
65
cdpkzjhglr(aauhwhncmh) = mmovwsutrp lokajoeqqc (zusflqssco )
Positive
01 Nov 2022
cdpkzjhglr(aauhwhncmh) = gibglblesp lokajoeqqc (zusflqssco )
Phase 2
Graves Ophthalmopathy
anti-TSHR-Ab positive
7
Batoclimab 680 mg for two weeks followed by 340 mg for four weeks
nstcpxtscv(dmhavmabeu) = n=2 for each whdflebegy (huqvtijfzj )
Positive
01 Nov 2022
Phase 2
65
Placebo (Administered via subcutaneous injection)
bazzcwmhbg = ugbnrwyjsx qutcehodzr (ijdbhryqbx, ttrzukrgqs - mncfqqkdsu)
-
22 Sep 2022
Phase 2
5
(Cohort 1: RVT-1401 680 mg/Week)
vgaoiwprmg = epynnsarmp ofithmipdc (jafmgfaecz, vgpfzjzanp - mpbfctncpq)
-
28 Jul 2022
(Cohort 2: RVT-1401 340 mg/Week)
pqymenxouz(riurmbwegl) = spbffmauxr kplytxbjdb (azhshobjxn, lumnruuvkm - twmmyegqfr)
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free